Regeneron’s lead counsel was Jonathan D. Polkes of White & Case LLP.

Sanofi and Regeneron have had a tough time of late with their PCSK9-class cholesterol drug, Praluent (alirocumab), as Amgen is attempting to get Praluent removed from the US market in an ongoing ...

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.